Is this the end of the cisplatin era in bladder cancer? It sure seems that way. The results here are no surprise based on the signal we saw in the metastatic setting.
It comes as no surprise that bispecific agents are moving up into earlier lines of therapy in multiple myeloma. Here, in the setting of early relapsed, anti-CD38 and –imid exposed patients, single agent teclistimab showed an 18mo progression-free survival benefit over PFd/Kd.
ASA alone may be just as good as Xarelto in the post-op, Deep vein thrombosis (DVT) prophylaxis setting after knee and hip replace. If this is replicated and confirmed, it seems quite compelling to stop using direct oral anticoagulants (DOACs) in this setting.
Finally, a game changer in metastatic pancreatic ductal adenocarcinoma (mPDAC), hopefully improved access will be available soon. Daxaronasib was not only more effective than chemo in the relapsed setting, but it was also more tolerable and with a better overall quality of life.
47% of the patients in this study had complete response (CR) on all oral regimen of decitabine–cedazuridine 5 days every 28 days plus venetoclax 400mg daily.
After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.
Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.
The median overall survival (OS) was 27·9 months with ivonescimab versus 23·7 months with tis.
Median progression-free survival was significantly longer with sac-TMT plus pembrolizumab than with pembrolizumab alone (not reached vs 5·7 m) this is regardless of PDL-1 expression (1-49 or >50).
Progression-free survival (PFS) was statistically significantly improved with addition of tucatinib versus placebo 24.9 v 16.3 months regardless of the presence/absence of BM or hormone receptor status.